Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (81-90 of 193) with videos related to

Pageof 20
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 4, 2008
Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytesOdette A Fahmi, Sherri Boldt, Mary Kish, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 30, 2025
Human cytochrome P4502C8 metabolizes repaglinide to 4'-hydroxyrepaglinide, not 3'-hydroxyrepaglinideRaman Sharma, Amanda Balesano, Angela C Doran, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2020
Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME StudyDouglas K Spracklin, Danny Chen, Arthur J Bergman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 6, 2005
Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolitesChristopher L Shaffer, Mithat Gunduz, Thomas N O'Connell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 13, 2025
Corrigendum to "Human cytochrome P4502C8 metabolizes repaglinide to 4'-hydroxyrepaglinide, not 3'-hydroxyrepaglinide" [Drug Metabolism and Disposition 53 (2025) 100177]Raman Sharma, Amanda Balesano, Angela C Doran, et al.
Current Drug Metabolism|November 6, 2007
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugsAleksandra Galetin, Laura K Hinton, Howard Burt, et al.
Chemical Research in Toxicology|June 24, 2009
Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and ratsDeepak Dalvie, Ping Kang, Michael Zientek, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 14, 2014
Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometrySusanna Tse, Louis Leung, Sangeeta Raje, et al.
The AAPS Journal|July 4, 2013
Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?Hongying Gao, Abigail Jacobs, Ronald E White, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 25, 2018
Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5Elaine Tseng, Gwendolyn D Fate, Gregory S Walker, et al.
Pageof 20

Showing results (81-90 of 193) with videos related to

Sort By:
Pageof 20
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 4, 2008
Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytesOdette A Fahmi, Sherri Boldt, Mary Kish, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 30, 2025
Human cytochrome P4502C8 metabolizes repaglinide to 4'-hydroxyrepaglinide, not 3'-hydroxyrepaglinideRaman Sharma, Amanda Balesano, Angela C Doran, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 21, 2020
Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME StudyDouglas K Spracklin, Danny Chen, Arthur J Bergman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 6, 2005
Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolitesChristopher L Shaffer, Mithat Gunduz, Thomas N O'Connell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 13, 2025
Corrigendum to "Human cytochrome P4502C8 metabolizes repaglinide to 4'-hydroxyrepaglinide, not 3'-hydroxyrepaglinide" [Drug Metabolism and Disposition 53 (2025) 100177]Raman Sharma, Amanda Balesano, Angela C Doran, et al.
Current Drug Metabolism|November 6, 2007
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugsAleksandra Galetin, Laura K Hinton, Howard Burt, et al.
Chemical Research in Toxicology|June 24, 2009
Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and ratsDeepak Dalvie, Ping Kang, Michael Zientek, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 14, 2014
Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometrySusanna Tse, Louis Leung, Sangeeta Raje, et al.
The AAPS Journal|July 4, 2013
Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?Hongying Gao, Abigail Jacobs, Ronald E White, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 25, 2018
Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5Elaine Tseng, Gwendolyn D Fate, Gregory S Walker, et al.
Pageof 20